Response assessment
Provide a sensitive measure of how strongly disease-associated markers respond to therapy.
MRD refers to the small number of malignant cells that may remain after treatment even when routine clinical assessments indicate remission.
Conventional morphology can confirm that the visible burden of disease has fallen substantially, but it may not reveal very low levels of residual malignant cells. Molecular and cellular MRD methods are used to evaluate disease at greater depth.
Obtain a high-disease-burden specimen and identify disease-associated molecular markers.
Quantify marker levels to evaluate the depth and kinetics of response.
Assess MRD at protocol-defined time points, such as end of induction, end of consolidation or around transplantation.
Track molecular changes over time and evaluate unexpected or emerging clonal signals.
Provide a sensitive measure of how strongly disease-associated markers respond to therapy.
MRD status and kinetics can add prognostic information in specific diseases and treatment settings.
Maintain a molecular record of known markers and identify changes that merit clinical review.
Method selection depends on disease biology, available markers, sample type, protocol requirements, sensitivity goals and local validation.
| Method | Primary signal | Common strengths | Considerations |
|---|---|---|---|
| Multiparameter flow cytometry | Abnormal cellular immunophenotype | Rapid, broad clinical experience, cell-level characterization | Requires viable, representative specimens and expert interpretation |
| Quantitative PCR | Defined molecular target | High specificity and established standardization for selected markers | Requires a suitable target and assay-specific calibration |
| Ig/TCR NGS | Patient-specific immune receptor rearrangement | High analytical depth, multiple-clone tracking, digital sequence record | Requires baseline marker identification and sufficient high-quality input |
Clinical testing, translational research, clinical trials and biopharma collaborations.